Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IGSF8 is a transmembrane protein belonging to the immunoglobulin superfamily. It acts as an innate immune checkpoint, inhibiting NK cell cytotoxicity by binding to KIR3DL2. It regulates cell movement, aggregation, proliferation, and morphology through interactions with tetraspanins and integrins. IGSF8 may also function as a tumor suppressor. It is frequently overexpressed in cancers and acts as an adhesion protein involved in T cell and NK cell interactions.
Inhibition of NK cell cytotoxicity via interaction with KIR receptors; Prevention of EGFR clustering/endocytosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin superfamily member 8 (IGSF8).